Asystole following Regadenoson administration: Review of literature, risk factors and management

Regadenoson, a selective A2A receptor agonist, is widely used for vasodilator stress myocardial perfusion imaging and has a superior adverse effect profile when compared with other agents. However, with widespread use, there have been several reported cases of Regadenoson induced bradyarrhythmias and even asystole in patients with no known conduction system disease. In this article, we report a case of asystole following Regadenoson administration, evaluate mechanisms and risk factors for Regadenoson induced bradyarrhythmias to better identify patients at risk. We also review the available treatment options and propose recommendations for limiting its risk.

Automated summary

Regadenoson, a selective A2A receptor agonist commonly used for vasodilator stress myocardial perfusion imaging, has been associated with rare but serious bradyarrhythmias, including asystole, in patients without known conduction system disease. Close monitoring and thorough risk assessment are essential for identifying and managing potential adverse effects in patients receiving Regadenoson.